Skip to main content

Table 6 Budget impact of alternative scale-up scenarios in the GAVI-eligible countries

From: Health and economic impact of rotavirus vaccination in GAVI-eligible countries

    Financial costsa
No Scale-up scenarios No. of children vaccinated Global society perspective (Total vaccination program costs) GAVI Alliance perspective (Vaccine cost support) Local government perspective (not including medical cost savings)b Local government perspective (including medical cost savings)b
   (in million) (US$, million) (US$, million) (US$, million) (US$, million)
1 Base-case rollout scenario (Table 2)      
  Vaccine efficacy based on the SAGE approach      
  Vaccine immunity waning (14% annually) 281.8 5,879 4,079 1,800 1,714
2 Base-case rollout scenario (Table 2)      
  Vaccine efficacy based on the SAGE approach      
  No vaccine immunity waning 281.8 5,879 4,079 1,800 1,707
3 Base-case rollout scenario (Table 2)      
  Vaccine efficacy adjusted for serotype distribution      
  Vaccine immunity waning (14% annually) 281.8 5,879 4,079 1,800 1,695
4c Base-case rollout scenario (Table 2)      
  Vaccine efficacy adjusted for serotype distribution      
  No vaccine immunity waning 281.8 5,879 4,079 1,800 1,686
5 (Modified) Wolfson et al. scenario [30]      
  Vaccine efficacy based on the SAGE approach      
  No vaccine immunity waning 410.5 8,573 5,943 2,630 2,472
6 (Modified) Wolfson et al. scenario [30]      
  Vaccine efficacy adjusted for serotype distribution      
  No vaccine immunity waning 410.5 8,573 5,943 2,630 2,414
7 A flat coverage of 70%      
  Vaccine efficacy based on the SAGE approach      
  No vaccine immunity waning 537.0 11,222 7,785 3,437 3,236
8 A flat coverage of 70%      
  Vaccine efficacy adjusted for serotype distribution      
  No vaccine immunity waning 537.0 11,222 7,785 3,437 3,170
  1. r = discount rate; YL = years of life; DALYs = disability-adjusted life-years; I$ = international dollars; SAGE = Strategic Advisory Group of Experts on Immunization.
  2. a All 10-year forecasts are based on the composite program cost of I$25 (corresponding to US$5 per vaccine dose) per vaccinated child and are not discounted.
  3. b The vaccine costs to local governments are based on the GAVI's co-financing scheme [32].
  4. c Base-case analysis.